2011
The Prognostic Value of MDM2, MDM4 (MDMX), and p53 in Early Stage Breast Cancer Treated with Breast Conserving Surgery and Radiotherapy
Neboori H, Wu H, Schiff D, Goyal S, Moran M, Yang J, Hirshfield K, Haffty B. The Prognostic Value of MDM2, MDM4 (MDMX), and p53 in Early Stage Breast Cancer Treated with Breast Conserving Surgery and Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s62-s63. DOI: 10.1016/j.ijrobp.2011.06.126.Peer-Reviewed Original Research
2010
Evaluation of Vascular Endothelial Growth Factor as a Prognostic Marker for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast-Conserving Therapy
Moran MS, Yang Q, Goyal S, Harris L, Chung G, Haffty BG. Evaluation of Vascular Endothelial Growth Factor as a Prognostic Marker for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast-Conserving Therapy. International Journal Of Radiation Oncology • Biology • Physics 2010, 81: 1236-1243. PMID: 21093162, DOI: 10.1016/j.ijrobp.2010.07.031.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnalysis of VarianceBiomarkers, TumorBlack PeopleBreast NeoplasmsDisease-Free SurvivalFemaleFollow-Up StudiesHumansMastectomy, SegmentalMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRadiotherapyTissue Array AnalysisVascular Endothelial Growth Factor AWhite PeopleConceptsEarly-stage breast cancerBreast-conserving therapyLocal relapse-free survivalRelapse-free survivalVascular endothelial growth factorEarly-stage breast cancer patientsLocal relapseBreast cancer patientsBreast cancerEndothelial growth factorVEGF expressionOverall survivalPrognostic valueCancer patientsTissue microarrayEstrogen receptor/progesterone receptor statusDistant metastasis-free survivalNodal relapse-free survivalGrowth factorProgesterone receptor statusInstitutional review board approvalMetastasis-free survivalLong-term outcomesMargin-negative patientsOverexpression of VEGF